Ocugen registers Phase 3 trial of OCU410 gene therapy for geographic atrophy in dry AMDAug 18Trial updateOCU410Ocugen
Ocugen reports Q2 2026 update with FDA clearance for OCU410 Phase 3 and $130M raiseAug 6Quarterly updateOCU400OCU410
Sign inSign in